1
Home
Companies

4SC

4SC
Leadership team

Clemens M. Doppler (Independent Chairman of Supervisory Board)

Irina Antonijevic (Independent Member of Supervisory Board)

Manfred Rüdiger (Independent Deputy Chairman of Supervisory Board)

Products/ Services
Biopharma, Biotechnology, Therapeutics
Number of Employees
0 - 50
Headquarters
Planegg, Bayern, Germany
Established
1997
Traded as
FRA:VSC
Social Media
URL
www.4sc.de/
Overview
Location

Summary
History
Mission
Vision
Key Team
Recognition and Award
References
Summary
4SC AG, a clinical-stage pharmaceutical company, engages in the discovery and development of targeted small molecule drugs, primarily for cancer diseases in Europe. Its compounds target cancer and autoimmune concurrent diseases in the areas of cancer metabolism, immune regulation, cancer therapy, epigenetics and haematology/oncology. The company's products in clinical development comprises SC1467 and SC16166 to treat various cancers, such as metastatic colorectal cancer, metastatic pancreatic cancer, chronic lymphocytic leukemia, acute myeloid leukemia, and multiple myeloma; and SC795, which is in preclinical development for the treatment of psoriasis.
History

4SC AG was founded in 1997. In 1998, 4SC began collaborating with Boehringer Mannheim GmbH in the area of cancer research. In 2004, 4SC acquired Hematolin GmbH, after which 4SC started its own operations in infectious diseases, including HIV, hepatitis B and hepatitis C. In 2011, 4SC begin to develop SC1467 as a candidate in metastatic colorectal cancer and, two years later, it promisingly advanced in the clinical development stage. 4SC is actively involved with strategic projects which allow 4SC to work with major partners to increase compliance in the development and commercialization of 4SC's potential future products.

Mission
Our mission is to discover, develop, and commercialize novel therapeutics to meet the needs of patients who suffer from chronic or life-threatening diseases.
Vision
4SC aspires to become a leader in the development and commercialization of new therapeutic agents for oncology and autoimmune conditions to improve the lives of patients.
Key Team

Helmut W. Jeggle (Independent Member of Supervisory Board)

Charles B. Epstein (Member International Scientific Expert Panel)

Helga Rübsamen-Schaeff (Independent Member of Supervisory Board)

Wolff Schmiegel (Member International Scientific Expert Panel)

Recognition and Awards
4SC AG has won several industry awards and distinctions including the BIOSPACE Top 10 Company award in 2018.
References

https://in.investing.com/equities/4sc-ag

https://finance.yahoo.com/quote/VSC.DE/profile?p=VSC.DE

https://www.crunchbase.com/organization/4sc

www.4sc.de/

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

4SC
Leadership team

Clemens M. Doppler (Independent Chairman of Supervisory Board)

Irina Antonijevic (Independent Member of Supervisory Board)

Manfred Rüdiger (Independent Deputy Chairman of Supervisory Board)

Products/ Services
Biopharma, Biotechnology, Therapeutics
Number of Employees
0 - 50
Headquarters
Planegg, Bayern, Germany
Established
1997
Traded as
FRA:VSC
Social Media
URL
www.4sc.de/